BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 29604436)

  • 1. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
    Shah N; Mohammad AS; Saralkar P; Sprowls SA; Vickers SD; John D; Tallman RM; Lucke-Wold BP; Jarrell KE; Pinti M; Nolan RL; Lockman PR
    Pharmacol Res; 2018 Jun; 132():47-68. PubMed ID: 29604436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current challenges in the management of breast cancer brain metastases.
    O'Sullivan CC; Davarpanah NN; Abraham J; Bates SE
    Semin Oncol; 2017 Apr; 44(2):85-100. PubMed ID: 28923217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
    Morikawa A; Peereboom DM; Thorsheim HR; Samala R; Balyan R; Murphy CG; Lockman PR; Simmons A; Weil RJ; Tabar V; Steeg PS; Smith QR; Seidman AD
    Neuro Oncol; 2015 Feb; 17(2):289-95. PubMed ID: 25015089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Landscape of combination therapy trials in breast cancer brain metastasis.
    Fares J; Kanojia D; Rashidi A; Ulasov I; Lesniak MS
    Int J Cancer; 2020 Oct; 147(7):1939-1952. PubMed ID: 32086955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.
    Perez EA
    Drug Resist Updat; 2016 Jan; 24():13-22. PubMed ID: 26830312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
    Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
    Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
    Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
    Zhang J; Zhang L; Yan Y; Li S; Xie L; Zhong W; Lv J; Zhang X; Bai Y; Cheng Z
    Drug Metab Dispos; 2015 Mar; 43(3):411-7. PubMed ID: 25547867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
    Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Diéras V; Müller V; Du Y; Currie SL; Hoch U; Tagliaferri M; Hannah AL; Cortés J;
    JAMA Oncol; 2022 Jul; 8(7):1047-1052. PubMed ID: 35552364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment strategies for breast cancer brain metastases.
    Bailleux C; Eberst L; Bachelot T
    Br J Cancer; 2021 Jan; 124(1):142-155. PubMed ID: 33250512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
    Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
    Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.
    Schlam I; Gatti-Mays ME
    Oncologist; 2022 Jul; 27(7):538-547. PubMed ID: 35598254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights and emerging therapies for breast cancer brain metastases.
    Lim E; Lin NU
    Oncology (Williston Park); 2012 Jul; 26(7):652-9, 663. PubMed ID: 22888567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
    Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
    Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
    Duchnowska R; Loibl S; Jassem J
    Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
    Shawky H; Tawfik H
    J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
    Leone JP; Duda DG; Hu J; Barry WT; Trippa L; Gerstner ER; Jain RK; Tan S; Lawler E; Winer EP; Lin NU; Tolaney SM
    Breast Cancer Res Treat; 2020 Jan; 179(1):113-123. PubMed ID: 31541381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.